Research programme: peptide therapeutics - Bayer/PeptiDream

Drug Profile

Research programme: peptide therapeutics - Bayer/PeptiDream

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer; PeptiDream
  • Class Macrocyclic compounds; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Cardiovascular disorders

Most Recent Events

  • 16 Nov 2017 Bayer and PeptiDream agree to collaborate on discovery and development of peptide therapeutics in Germany and Japan
  • 16 Nov 2017 Early research in Cancer in Japan, Germany (unspecified route)
  • 16 Nov 2017 Early research in Cardiovascular disorders in Japan, Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top